Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

Yahoo Finance • 2 days ago

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best low-priced pharma stocks on this list. TheFly reported on June 25 that Guggenheim raised i... Full story

Yahoo Finance • 2 days ago

Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best low-priced pharma stocks on this list. TheFly reported on June 18 that Jefferies a... Full story

Yahoo Finance • last month

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Key Points Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million. Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales an... Full story

Yahoo Finance • 2 months ago

Amylyx Pharmaceuticals Q1 Earnings Call Highlights

Amylyx Pharmaceuticals logo Key Points Avexitide Phase 3 LUCIDITY completed dosing and the company says it’s on track for a near-term top-line readout, with management and the CFO pointing to potential readout timing around Q3 2026. Expa... Full story

Yahoo Finance • 3 months ago

Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On March 24, Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stated that the final subject in the Phase 3 Lucidi... Full story

Yahoo Finance • 4 months ago

Pre-Market Earnings Report for March 3, 2026 : AZO, TGT, SE, VIK, ONON, BBY, THO, SRRK, SRAD, KTB, MRX, AMLX

The following companies are expected to report earnings prior to market open on 03/03/2026. Visit our Earnings Calendar for a full list of expected earnings releases. AutoZone, Inc. (AZO)is reporting for the quarter ending February 28,... Full story

Yahoo Finance • 7 months ago

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Key Points Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million. PHVS is a new addition, accounting for 4.9% of 13F AUM, which p... Full story

Yahoo Finance • 7 months ago

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?

Key Points Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter. Saturn V now holds 4.6 million... Full story

Yahoo Finance • 7 months ago

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets

Key Points Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. The overall position increased in value by $20 million from quarter to quarter. Saturn V now holds nearly 2.7 mill... Full story

Yahoo Finance • 8 months ago

December 2026 Options Now Available For Amylyx Pharmaceuticals (AMLX)

Investors in Amylyx Pharmaceuticals Inc (Symbol: AMLX) saw new options become available today, for the December 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so... Full story

Yahoo Finance • 8 months ago

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) - Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 8 months ago

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 8 months ago

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 8 months ago

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 8 months ago

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Amylyx Pharmaceuticals,... Full story

Yahoo Finance • 9 months ago

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 9 months ago

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to sha... Full story

Yahoo Finance • 9 months ago

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 9 months ago

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX): Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) as securities fraud class a... Full story

Yahoo Finance • 10 months ago

Amylyx Pharmaceuticals prices $175M public offering

* Amylyx Pharmaceuticals (NASDAQ:AMLX [https://seekingalpha.com/symbol/AMLX]) priced [https://seekingalpha.com/pr/20227278-amylyx-pharmaceuticals-announces-pricing-of-175-million-underwritten-public-offering-of] an underwritten public of... Full story